Çelik et al., 2023 - Google Patents

The CXCL9/10/11-CXCR3 axis as a predictor of COVID-19 progression: a prospective, case-control study

Çelik et al., 2023

View HTML
Document ID
12070356282313695237
Author
Çelik N
Çelik O
Laloğlu E
Özkaya A
Publication year
Publication venue
Revista da Sociedade Brasileira de Medicina Tropical

External Links

Snippet

Background: This study examined the relationship between levels of the chemokines CXCL9, CXCL10, CXCL11, and CXCR3 and mortality in patients with COVID-19.. Methods: A total of 71 patients hospitalized with COVID-19 and 35 health workers with no symptoms …
Continue reading at www.scielo.br (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Similar Documents

Publication Publication Date Title
Kwon et al. Factors of severity in patients with COVID-19: cytokine/chemokine concentrations, viral load, and antibody responses
Ni et al. Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID‐19
Bajpai et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial
Keske et al. Appropriate use of tocilizumab in COVID-19 infection
Luo et al. Circulating levels of IL‐2, IL‐4, TNF‐α, IFN‐γ, and C‐reactive protein are not associated with severity of COVID‐19 symptoms
Masur et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection
Levine et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study
Liu et al. Viral sepsis is a complication in patients with Novel Corona Virus Disease (COVID-19)
Zeng et al. The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series
Chiche et al. Interferon-γ production by natural killer cells and cytomegalovirus in critically ill patients
Can et al. Effect of IL‐6, IL‐8/CXCL8, IP‐10/CXCL 10 levels on the severity in COVID 19 infection
Fu et al. An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19
Georgakopoulou et al. The impact of peripheral eosinophil counts and eosinophil to lymphocyte ratio (ELR) in the clinical course of COVID-19 patients: A retrospective study
Çelik et al. The CXCL9/10/11-CXCR3 axis as a predictor of COVID-19 progression: a prospective, case-control study
Lachmann et al. A comparative phase 1 clinical trial to identify anti-infective mechanisms of vitamin D in people with HIV infection
Lee et al. Disseminated adenovirus infection in cancer patients presenting with focal pulmonary consolidation
Katzenstein et al. Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis
Zhu et al. Interferon-α plus ribavirin yields 98% sustained virologic response in children aged 1–5 years with iatrogenic chronic hepatitis C
Del Bello et al. Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation
Cho et al. Plasminogen activator inhibitor-1 in sputum and nasal lavage fluids increases in asthmatic patients during common colds
Feld et al. Peginterferon-lambda for the treatment of COVID-19 in outpatients
Kazempour et al. Anti-inflammatory Effect of Metronidazole in Hospitalized Patients with Pneumonia due to COVID-19
Abu Shanap et al. Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection
JP6206953B2 (en) Method for testing the likelihood of developing adult T-cell leukemia
Ren et al. Analysis of the dynamic relationship between immune profiles and the clinical features of patients with COVID-19